biote (NASDAQ:BTMD) Issues Earnings Results

biote (NASDAQ:BTMD) released its earnings results on Wednesday. The company reported $0.01 earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $43.33 million during the quarter, compared to analyst estimates of $44.01 million. biote had a negative net margin of 1.08% and a negative return on equity of 8.84%.

Here are the key takeaways from biote’s conference call:

• Procedure revenue remained under pressure: Q3 revenue fell 9.6% to $43.3 million, while procedure revenue declined 15.1% to $28.9 million, with the January recall contributing to slower-than-expected recovery. Management cited modest improvement in average daily procedure volume but said sustained growth still requires work.
• Profitability declined sharply year over year: Net income was $0.6 million versus $9.2 million a year earlier, and diluted EPS was $0.01 versus $0.22. Gross margin fell to 67.7% from 71.8%, partly due to reliance on lower-margin third-party pellets.
• Gross margin showed sequential recovery: It improved 231 basis points from Q2 as pellet sourcing shifted back toward Biote’s internally manufactured supply. Asteria Health was back to pre-recall levels and expected to supply more than half of shipped pellets.
• Supplements continued to grow: Revenue rose 7.3% to $12.0 million, primarily driven by the e-commerce channel.
• Full-year 2026 guidance was maintained at revenue above $175 million and Adjusted EBITDA above $25 million. Management pointed to encouraging procedure trends, while emphasizing that improved sales productivity, clinic retention, and practitioner engagement remain necessary to restore growth.

biote Stock Performance

Shares of biote stock traded up $0.00 during trading on Friday, hitting $1.04. 42,881 shares of the company’s stock were exchanged, compared to its average volume of 234,220. biote has a 52-week low of $0.99 and a 52-week high of $2.90. The stock has a market capitalization of $37.40 million, a price-to-earnings ratio of -10.35 and a beta of 1.73. The business has a 50-day simple moving average of $1.26 and a 200-day simple moving average of $1.81.

Analyst Ratings Changes

Several equities analysts have commented on BTMD shares. B. Riley Financial cut their price objective on biote from $2.00 to $1.50 and set a “neutral” rating on the stock in a research report on Monday, August 10th. TD Cowen cut their price target on biote from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Finally, Weiss Ratings cut shares of biote from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $2.50.

Insiders Place Their Bets

In other news, Chairman Marc Beer acquired 115,950 shares of the business’s stock in a transaction on Monday, August 10th. The stock was bought at an average price of $1.53 per share, with a total value of $177,403.50. Following the completion of the acquisition, the chairman owned 223,744 shares of the company’s stock, valued at approximately $342,328.32. This represents a 107.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 32.40% of the company’s stock.

About biote

Biote Inc (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services.

The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.